<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116634</url>
  </required_header>
  <id_info>
    <org_study_id>rokhsareh</org_study_id>
    <secondary_id>stem cell injection in ALS</secondary_id>
    <nct_id>NCT02116634</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alzahra Hospital, Iran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alzahra Hospital, Iran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whether the mesenchymal injection on ALS patients is effective or not?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After and before transplantation, all of the patients will visit by experience neurologist
      and evaluate with EMG (electromyography) and spirometry procedure and clinical progression of
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Because economic problems
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Intrathecal injection of autologous mesenchymal stem cells in improving the symptoms of ALS</measure>
    <time_frame>every 6 months up 2 years after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALS-FRS(functional rating scale) score and EMG scale</measure>
    <time_frame>before transplatation and at 6 months, 12months, 18 months and 24 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (forced vital capacity)and DWSE±QoL score</measure>
    <time_frame>before transplantation and every 6 months up 2 years after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cell</intervention_name>
    <description>intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline</description>
    <arm_group_label>mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. sporadic ALS according to escorial criteria

          2. onset of disease with spinal cord involvement, Less than 3 years of disease onset with
             disease progression at 6 past months

          3. mild to moderate spinal and bulbar disability,at least having score3 in swallowing, 2
             in chewing and waking in ALS-FRS and FVC(functional vital capacity) equal or more than
             50% of prediction amount

          4. normal polysomnography

          5. Signed consent form

        Exclusion Criteria:

          1. pregnancy or lactation,

          2. vascular disease,diabetes, systemic disease as cancer, autoimmune , liver or
             hematologic disease

          3. Hospitalization due to serious illness in the last two months

          4. survival time less than two years

          5. Hypersensitivity to any component used in the cell culture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>keivan basiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan neurosciences research center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurosciences Research Center</name>
      <address>
        <city>Isfahan</city>
        <zip>0098311</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2014</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alzahra Hospital, Iran</investigator_affiliation>
    <investigator_full_name>rokhsareh meamar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

